Loading...
•
Jun 30, 2023
Castle Biosciences Q2 2023 Earnings Report
Reported a 44% revenue increase and a 52% increase in total test reports compared to Q2 2022.
Key Takeaways
Castle Biosciences reported strong Q2 2023 results, with a 44% increase in revenue to $50.1 million and a 52% increase in total test reports delivered. The company raised its full-year 2023 revenue guidance to at least $180 million.
Revenues were $50.1 million, a 44% increase compared to the same period in 2022.
Delivered 16,820 total test reports, a 52% increase compared to the same period in 2022.
Gross margin for the quarter was 73%, and adjusted gross margin was 78%.
Net loss for the second quarter was $(18.8) million.
Forward Guidance
Castle Biosciences is increasing its guidance for anticipated total revenue in 2023 to at least $180 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...